The eczema and asthma medication Dupixent (dupilumab) has been linked to an increased risk of a type of lymphoma known as Cutaneous T-Cell Lymphoma (CTCL).
If you or a loved one used Dupixent to treat asthma or eczema and were diagnosed with CTCL – or if your lymphoma symptoms became worse after using this drug – you may be eligible to file lawsuit and receive compensation.
Start your Dupixent lawsuit today by contacting the lawyers at Hissey Mulderig & Friend. You can reach us by calling our office toll-free at 1-866-806-8117, or by sending us a message using our free claims submission form, located on the right side of this page.
➢ Dupixent & T-Cell Lymphoma
Patients who were treated with Dupixent may be at risk of developing a rare type of blood cancer affecting the skin known as Cutaneous T-Cell Lymphoma (CTCL).
Two different types of Cutaneous T-Cell Lymphoma have been linked to the use of Dupixent:
- Mycosis fungoides are the most common form of CTCL, which can cause rashes or bumps to form on the skin.
- Sezary syndrome is a rare but more aggressive form of the disease, affecting both the skin and the blood.
Some of the most common symptoms of Cutaneous T-Cell Lymphoma include:
- Fatigue or tiredness
- Itchiness
- Red rashes, bumps, or plaques on the skin
- Swollen glands or lymph nodes
- Weight loss
The continued use of Dupixent after being diagnosed with CTCL may also cause the symptoms of this condition to become worse. In some cases, patients may be mistakenly diagnosed with eczema symptoms that are, in fact, caused by lymphoma, which could increase their risk of severe illness or lead to death.
➢ Studies Link Dupixent to Increased Lymphoma Risk
Several studies about the side effects of Dupixent have linked the drug to an increased risk of Cutaneous T-Cell Lymphoma.
According to two studies published in 2024 by the Journal of the American Academy of Dermatology and the journal Dermatologic Therapy found patients treated with Dupixent at least three times more likely to develop TCL than patients who never used the drug.
Another study, published in 2025 by the European Respiratory Journal, found that asthma patients treated with Dupixent were 4.5-times more likely to be diagnosed with lymphoma than those who received another type of asthma treatment. According to the study, patients who used Dupixent for more than 16 weeks were 14-times more likely to develop lymphoma.
In September 2025, the Food and Drug Administration (FDA) announced that it had received more than 300 reports of patients who had used Dupixent for eczema or asthma and been diagnosed with CTCL.
In response to these reports, the agency launched a formal investigation to determine whether a warning label about the link between Dupixent and lymphoma should be added to the drug’s label.
➢ Dupixent Lawsuits Over T-Cell Lymphoma
The first lawsuit against Regeneron and Sanofi-Aventis, the manufacturers of Dupixent, was filed in October 2025 on behalf of a woman who died from T-cell lymphoma after being treated with the drug.
Lawsuits filed on behalf of Dupixent patients who developed lymphoma have alleged that its manufacturers failed to properly warn users about their risk of developing CTCL and that the drug may cause lymphoma symptoms to worsen or become more aggressive.
Some Dupixent lawsuits have also alleged users may have continued using the drug after they developed Cutaneous T-Cell Lymphoma because they believe that their symptoms were caused by eczema, and not cancer. Continuing to use Dupixent after they had developed cancer may have caused the lymphoma to develop more rapidly than it would have were they not taking the drug.
As of December 2025, the Dupixent litigation is currently in its early stages. Legal experts have predicted that many more lawsuits will be filed as the hundreds of thousands of patients who used this drug become aware of the link between Dupixent and T-cell lymphoma.
➢ Start Your Dupixent Claim Today
If you or a loved one took Dupixent to treat asthma or eczema and were diagnosed with Cutaneous T-Cell Lymphoma – or if your symptoms became worse after using this drug – you may qualify to file a lawsuit against Regeneron and Sanofi-Aventis.
Dupixent users who qualify may be eligible to receive compensation for their illness, as well as medical bills, lost wages, and wrongful death.
Start the process of filing your claim today by contacting the law firm of Hissey, Mulderig & Friend using the free claims submission form, located at the top of this page. You can also reach us by calling our office toll-free at 1-866-806-8117.
